|
|
|
| Effects of succinic metoprolol on blood pressure and left ventricular myocardial remodeling in young and middle-aged patients with hypertension |
| YANG Chunqiang*, LI Yuan, LI Yan |
| Department of Cardiology, Rizhao Central Hospital, Rizhao 276800, Shandong, P. R. China |
|
|
|
|
Abstract Objective To investigate the effects of succinic metoprolol sustained release tablets on blood pressure and myocardial remodeling in the treatment of young and middle-aged patients with hypertension.Methods The young and middle-aged hypertensive patients with mild to moderate first diagnosed with resting heart rate of >80 times /min were randomly divided into the succinate metoprolol sustained release tablet treatment group (n=81) and the losartan control group (n=79) for 6 months of treatment. Heart rate (HR), diastolic blood pressure (DBP) and systolic blood pressure (SBP) were observed before and after the treatment in both groups. Before and after the treatment, ultrasonic measurement was conducted on left atrial diameter (LA), interventricular septum thickness (IVST), left ventricular posterior wall thickness (LVPWT), left ventricular systolic immaturity Diameter (LVDs), left ventricular diastolic diameter (LVDd), left ventricular diastolic idle volume(LVEDV), left ventricular ejection fraction (EF), left ventricular myocardial mass index (LVMI), mitral peak early diastolic flow velocity (PFVE), and the largest room velocity (PFVA). Left ventricular mass index (LVMI) and E/A ratio were calculated and analyzed statistically.Results IVST, LVPWT and LVMI in both groups were reduced compared with those before the treatment. The comparison before and after the treatment was statistically significant (P<0.05), suggesting improvement of left ventricular hypertrophy. There was no change in EF before and after the treatment (P>0.05), and left ventricular systolic function was not affected. After the treatment, PFVE and E/A increased, PFVA decreased in both groups, there were significant differences before and after the treatment (P<0.05), and left ventricular diastolic function improved.Conclusion Succinic metoprolol sustained release tablets can effectively reduce blood pressure and heart rate, reverse left ventricular myocardial remodeling and improve left ventricular diastolic function in young and middle-aged patients with hypertension.
|
|
Received: 07 December 2020
|
|
|
|
|
|
[1] DAHLÖF B, DEVEREUX R B, KJELDSEN S E, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol[J]. Lancet, 2002, 359(9311): 995-1003.
[2] DAHLÖF B, SEVER P S, POULTER N R, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial[J]. Lancet, 2005, 366(9489): 895-906.
[3] 施仲伟,冯颖青,王增武,等.β受体阻滞剂在高血压应用中的专家共识[J].中国医学前沿杂志(电子版),2019,11(4):29-39.
[4] DEVEREUX R B, ALONSO D R, LUTAS E M, et al. Echocardiographic assessment of left ven-tricular hypertrophy: Comparison to necropsy findings[J]. Am J Cardiol,1986,57(6):450-458.
[5] MANCIA G, FAGARD R, NARKIEWICZ K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC)[J]. Eur Heart J, 2013, 34(28): 2159-2219.
[6] LAW M R, WALD N J, MORRIS J K, et al. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials[J]. BMJ, 2003, 326(7404): 1427.
[7] 施仲伟,冯颖青,林金秀,等.高血压患者心率管理中国专家共识[J].中国医学前沿杂志(电子版),2017,9(8):29-36.
[8] DICKERSON J E, HINGORANI A D, ASHBY M J, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes[J]. Lancet, 1999, 353(9169): 2008-2013.
[9] LÓPEZ-SENDÓN J, SWEDBERG K, MCMURRAY J, et al. Expert consensus document on beta-adrenergic receptor blockers[J]. Eur Heart J, 2004, 25(15): 1341-1362.
[10] FRISHMAN W H. Beta-adrenergic receptor blockers in hypertension: Alive and well[J]. Prog Cardiovasc Dis, 2016, 59(3): 247-252. |
|
|
|
